Drugs for inflammatory and fibrotic diseases

Mirador Therapeutics is pioneering advancements in precision medicine specifically targeting immune-mediated inflammatory and fibrotic diseases. Central to their approach is the proprietary Mirador360™ development engine, which integrates cutting-edge biology, multi-modal data, and advanced analytics. This engine is designed to enhance the speed and accuracy of drug development, leveraging a vast repository of immune-mediated disease data that includes over two million human molecular profiles. By utilizing this comprehensive dataset, Mirador aims to identify new therapeutic targets and develop innovative treatments that address significant unmet medical needs in the field of immunology and inflammation.

In a strategic collaboration with 23andMe, Mirador Therapeutics is set to enhance its research capabilities by incorporating de-identified genetic and phenotypic data from the 23andMe database, the largest crowdsourced platform for genetic research. This partnership is expected to supercharge Mirador's mission to deliver transformational precision therapies, combining insights from 23andMe with the advanced functionalities of the Mirador360™ engine. The collaboration underscores Mirador's commitment to revolutionizing the treatment landscape for patients suffering from chronic immune-mediated conditions, ultimately aiming to provide better and more effective therapeutic options.

United States

Mirador Therapeutics is a next-generation precision medicine company focused on immunology and inflammation. The company's Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to accelerate the next generation of precision medicines for immune-mediated diseases.

Mirador Therapeutics

Company Details